Protective effect of recombinant human erythropoeitin against cisplatin cytotoxicity and genotoxicity in cultured Vero cells

Experimental and Toxicologic Pathology

Volumn 65, Issue 1-2, 2013, Pages 181-187

  Rjiba Touati, Karima ^a   Ayed Boussema, Imen ^a   Belarbia, Anis ^b   Azzebi, Awatef ^b   Achour, Abdellatif ^b   Bacha, Hassen ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b University Hospital of Sahloul   (Tunisia)

Author keywords

Apoptosis; Cisplatin; Cytoprotection; Genoprotection; RhEPO

Indexed keywords

CASPASE 3; CISPLATIN; DNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENOTOXICITY; NONHUMAN; PROTEIN EXPRESSION; VERO CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CISPLATIN; COMET ASSAY; CYTOPROTECTION; DNA DAMAGE; ERYTHROPOIETIN; IMMUNOBLOTTING; MUTAGENS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VERO CELLS;

EID: 84870239491     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2011.08.004     Document Type: Article

References (74)

1. Ahmida M.H., Abdel-Gayoum A.A., El-Fakhri M.M. Effect of spironolactone on cisplatin-induced nephrotoxicity in rabbits. Hum Exp Toxicol 2001, 20:453-459.
2. Ali B.H., Al Moundhri M.S. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006, 44:1173-1183.
3. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990, 87:5978-5982.
4. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl Acad Sci USA 1994, 91:3974-3978.
5. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin Nephrol 2003, 23:460-464.
6. Baek S.M., Kwon C.H., Kim J.H., Woo J.S., Jung J.S., Kim Y.K. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003, 142:178-186.
7. Baliga R., Zhang Z., Baliga M., Ueda N., Shah S.V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998, 53:394-401.
8. Boulikas T., Vougiouka M. Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 2003, 10:1663-1682.
9. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
10. Chang M.S., Kim doR, Ko E.B., Choi B.J., Park S.Y., Kang S.A., et al. Treatment with Astragali radix and Angelicae radix enhances erythropoietin gene expression in the cyclophosphamide-induced anemic rat. J Med Food 2009, 12:637-642.
11. Carvalho Rodrigues M.A., Rodrigues J.L., Martins N.M., Barbosa F., Curti C., Santos N.A.G., et al. Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion 2010, 10:46-53.
12. Chipuk J.E., Green D.R. Dissecting p53-dependent apoptosis. Cell Death Differ 2006, 13:994-1002.
13. Chirino Y.I., Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009, 61:223-242.
14. Collins A.R., Dusinska M., Gedik C.M., Stetina R. Oxidative damage to DNA: do we have a reliable biomarker?. Environ Health Perspect 1996, 104:465-469.
15. Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 1998, 24:265-281.
16. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001, 412:641-647.
17. Dos Santos N.A., Martins N.M., Curti C., Pires Bianchi L., dos Santos A.C. Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats. Chem Biol Interact 2007, 170:177-186.
18. Fenoglio C., Boicelli C.A., Ottone M., Addario C., Chiari P., Viale M. Effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney. Anticancer Drugs 2002, 13:1043-1054.
19. Fuertesa M.A., Castillab J., Alonsoa C., Perez J.M. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003, 10:257-266.
20. Gamal el-Din A.M., Al-Bekairi A.M. Carvedilol, a beta adrenoceptor blocker with antioxidative potential, attenuates cisplatin-induced nephrtotoxicity in rats. J Appl Sci Res 2006, 2:331-335.
21. Ghezzi P., Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004, 11:37-44.
22. Gobe G.C., Endre Z.H., Johnson D.W. Administration of erythropoietin and its derivatives in renal disease: Advantages, mechanisms and concerns. Drug Discov Today: Ther Strat 2007, 4:79-84.
23. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 2001, 59:657-663.
24. Gouva C., Nikolopoulos P., Ioannidis J.P., Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004, 66:753-760.
25. Grasso G., Sfacteria A., Cerami A., Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?. Neuroscientist 2004, 10:93-98.
26. Grimm C., Wenzel A., Groszer M., Mayser H., Seeliger M., Samardzija M., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against lightinduced retinal degeneration. Nat Med 2002, 8:718-724.
27. Hanigan M.H., Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003, 1:47-61.
28. Hartmann J.T., Fels L.M., Knop S., Stolt H., Kanz L., Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000, 18:281-289.
29. Hanlon P.R., Fu P., Wright G.L., Steenbergen C., Arcasoy M.O., Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB 2005, 19:1323-1325.
30. Hu Y.J., Chen Y., Zhang Y.Q., Zhou M.Z., Song X.M., Zhang B.Z., et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997, 56:331-341.
31. Imamura R., Moriyama T., Isaka Y., Namba Y., Ichimaru N., Takahara S., et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007, 83:1371-1379.
32. Jagadeeswaran R., Thirunavukkarasu C., Gunasekaran P., Nalini R., Sakthisekaran D. In vitro studies on the selective cytotoxic effect of crocetin and quercetin. Fitoterapia 2000, 71:395-399.
33. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004, 43:649-659.
34. Jo S.K., Cho W.Y., Sung S.A., Kim H.K., Won N.H. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 2005, 67:458-466.
35. Jungers P., Choukroun G., Oualim Z., Robino C., Nguyen A.T., Man N.K. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001, 16:307-312.
36. Kang D.H., Park E.Y., Yu E.S., Lee Y.S., Yoon K.I. Renoprotective effect of erythropoietin (EPO): possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int 2005, 67:1683.
37. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006, 354:2034-2045.
38. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf 2001, 24:19-38.
39. Koyner J.L., Sher Ali R., Murray P.T. Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury?. Nephron Exp Nephrol 2008, 109:109-117.
40. Kuriyama S., Tomonari H., Yoshida H., Hashimoto T., Kawaguchi Y., Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997, 77:176-185.
41. Lappin T.R., Maxwell A.P., Johnston P.G. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002, 20:485-492.
42. Lee S.H., Li C., Lim S.W., Ahn K.O., Choi B.S., Kim Y.S., et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005, 25:64-76.
43. Links M., Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999, 57:293-308.
44. Liu J., Li C., Qu W., Leslie E., Bonifant C.L., Buzard G.S., et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther 2004, 3:709-714.
45. Mammis A., McIntosh T.K., Maniker A.H. Erythropoietin as a neuroprotective agent in traumatic brain injury. Surg Neurol 2009, 71:527-531.
46. McPherson R.J., Demers E.J., Juul S.E. Safety, of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology 2007, 91:36-43.
47. Morishita E., Masuda S., Nagao M., Yasuda Y., Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997, 76:105-116.
48. Naziroglu M., Karaoglu A., Aksoy A.O. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004, 195:221-230.
49. Pallet N., Bouviera N., Legendre C., Beaunea P., Therveta E., Choukrounc G., et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010, 61:71-75.
50. Park M.S., De Leon M., Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002, 13:858-865.
51. Prasad S.B., Rosangkima G., Kharbangar A. Structural and biochemical changes in mitochondria after cisplatin treatment of Dalton's lymphoma-bearing mice. Mitochondrion 2010, 10:38-45.
52. Ratcliffe P.J., O'Rourke J.F., Maxwell P.H., Pugh C.W. Oxygen sensing, hypoxiainducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998, 201:1153-1162.
53. Saad S.Y., Najjar T.A., Noreddin A.M., Al-Rikabi A.C. Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: scheduled ependent study. Pharmacol Res 2001, 43:193-198.
54. Saad S.Y., Al-Rikabi A.C. Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 2002, 48:42-48.
55. Salahudeen A.K., Haider N., Jenkins J., Joshi M., Patel H., Huang H., et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2008, 294:F1354.
56. Saleh S., El-Demerdash E. Protective effects of l-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005, 97:91-97.
57. Santoso J.T., Lucci 3rd J.A., Coleman R.L., Schafer I., Hannigan E.V. Saline, mannitol, and frusemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003, 52:13-18.
58. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004, 15:2115-2124.
59. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
60. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184-191.
61. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl Acad Sci USA 2001, 98:4044-4049.
62. Sun Y., Zhou C., Polk P., Nanda A., Zhang J.H. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab 2004, 24:259-270.
63. Taguchi T., Nazneen A., Abid M.R., Razzaque M.S. Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol 2005, 148:107-121.
64. Tayem Y., Johnson T.R., Mann B.E., Green C.J., Motterlini R. Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. Am J Physiol Renal Physiol 2006, 290:789-794.
65. Terasima T., Yasukawa M. Biological properties of Vero cells derived from the present stock. Vero cells: origin, properties and biomedical applications 1988, 32-35. Department of Microbiology, School of Medicine, Chiba University, Chiba, Japan. B. Simizu, T. Terasima (Eds.).
66. Vairano M., Russo C.D., Pozzoli G., Battaglia A., Scambia G., Tringali G. Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci 2002, 16:584-592.
67. Vesey D.A., Cheung C., Pat B., Endre Z., Gobe G., Johnson D.W. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004, 19:348-355.
68. Wang H.B., Wang L.M., Zhang R.X., Liang R. Effects of erythropoietin on the expression of aquaporin-2 after renal ischemia-reperfusion injury: experiment with rats. Zhonghua Yi Xue Za Zhi 2008, 88:2710-2714.
69. Westenfelder C., Biddle D.L., Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999, 55:808-820.
70. Winczura P., Jassem J. Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev 2010, 36:268-275.
71. Wojchowski D.M., Gregory R.C., Miller C.P., Pandit A.K., Pircher T.J. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999, 253:143-156.
72. Xiao T., Choudhary S., Zhang W., Ansari N.H., Salahudeen A. Possible role of oxidative stress in cisplatin induced apoptosis in LLC-PK1 cells. J Toxicol Environ Health 2003, 66:469-479.
73. Yamate J., Sato K., Machida Y., Ide M., Sato S., Nakatsuji S. Cisplatin-induced rat renal interstitial fibrosis: a possible pathogenesis based on the data. J Toxicol Pathol 2000, 13:237-247.
74. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity. Am J Med Sci 2007, 334:115-124.